Viking Therapeutics' new GLP-1 weight loss pill, VK2735, helped patients shed 12.2% of their body weight in 13 weeks. The pill is proving "safe and well-tolerated." However, one-fifth of participants ...

VK2735 shows strong early weight-loss data, positioning Viking as a potential third major player in the booming GLP-1 obesity drug market. Despite a sharp stock decline, Viking is well-funded, with ...

Viking Therapeutics' shares tanked recently after its oral drug, VK2735, spooked investors with a high discontinuation rate. However, it achieved weight loss results similar to Eli Lilly's drug.